| Identification | Back Directory | [Name]
Lensiprazine | [CAS]
327026-93-7 | [Synonyms]
SLV314
SLV-314
SLV 314
327026-93-7
lensiprazine
(2R)-8-[4-[3-(5-fluoro-1H-indol-3-yl)propyl]piperazin-1-yl]-2-methyl-4H-1,4-benzoxazin-3-one
(2R)-8-[4-[3-(5-Fluoro-1H-indol-3-yl)propyl]-1-piperazinyl]-2-methyl-2H-1,4-benzoxazin-3(4H)-one
(R)-8-(4-(3-(5-fluoro-1H-indol-3-yl)propyl)piperazin-1-yl)-2-methyl-2H-benzo[b][1,4]oxazin-3(4H)-one
2H-1,4-Benzoxazin-3(4H)-one, 8-[4-[3-(5-fluoro-1H-indol-3-yl)propyl]-1-piperazinyl]-2-methyl-, (2R)- | [Molecular Formula]
C24H27FN4O2 | [MDL Number]
MFCD13194766 | [MOL File]
327026-93-7.mol | [Molecular Weight]
422.5 |
| Hazard Information | Back Directory | [Uses]
Lensiprazine is a potent dopamine D2 receptor (D2R) antagonist that acts as a serotonin reuptake inhibitor. Lensiprazine can be used to study bipolar disorder and schizophrenia[1][2][3]. | [References]
[1] Bollu R, et al. Potential anti-proliferative agents from 1, 4-benzoxazinone-quinazolin-4 (3H)-one templates[J]. Bioorganic & Medicinal Chemistry Letters, 2017, 27(24): 5481-5484. DOI:10.1016/j.bmcl.2017.10.044
[2] Lange J H M, et al. Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs[J]. Journal of medicinal chemistry, 2007, 50(21): 5103-5108. DOI:10.1021/jm070516u
[3] Rauly-Lestienne I, et al. Differential profile of typical, atypical and third generation antipsychotics at human 5-HT 7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties[J]. Naunyn-Schmiedeberg's archives of pharmacology, 2007, 376: 93-105. DOI:10.1007/s00210-007-0182-6 |
|
|